Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8277402 | 0.88 | L3MBTL1 (0.77) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 | |
| SCHEMBL1289638 | 0.86 | L3MBTL1 (0.69) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 | |
| SCHEMBL147292 | 0.84 | L3MBTL1 (0.77) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 | |
| SCHEMBL147293 | 0.84 | L3MBTL1 (0.77) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 | |
| SCHEMBL9313874 | 0.83 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 | |
| SCHEMBL16438801 | 0.83 | L3MBTL1 (0.75) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 | |
| SCHEMBL11147480 | 0.83 | L3MBTL1 (0.75) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 | |
| SCHEMBL7827827 | 0.83 | ALDH1A1 (0.76) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 | |
| SCHEMBL23748676 | 0.81 | RNF4 (0.73) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 | |
| SCHEMBL22931143 | 0.81 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1HTTHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285803-B | Preparation method of 6-hydroxy-3, 4-dihydro-2 (1H) -quinolone | 湖南复瑞生物医药技术有限责任公司 | 2024-04-09 | — | — | CN | claimed |
| CN-111285803-A | Preparation method of 6-hydroxy-3, 4-dihydro-2 (1H) -quinolone | 湖南复瑞生物医药技术有限责任公司 | 2020-06-16 | — | — | CN | claimed |
| US-6740758-B2 | REACTING P-ANISIDINE WITH 3-CHLOROPROPIONYL CHLORIDE IN PRESENCE OF SODIUM BICARBONATE AND TOLUENE AND CYCLIZING | TEVA PHARMACEUTICAL INDUSTRIES (IL) | 2004-05-25 | — | — | US | claimed |
| US-20040034228-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)-3-chloropropionamide | MENDELOVICI MARIOARA (IL) | 2004-02-19 | — | — | US | claimed |
| US-6660773-B2 | Reacting anisidine with 3-chloropropionamide to form N-(4-methoxy phenyl)-3-chloropropionamide; intramolecular Friedel-Crafts cyclization with a Lewis acid; decomposition of salt; demethylation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-12-09 | — | — | US | claimed |
| US-20030176703-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)-3-chloropropionamide | MENDELOVICI MARIOARA (IL) | 2003-09-18 | — | — | US | claimed |
| US-6525201-B2 | Amidation of p-anisidine with 3-chloropropionyl chloride; cyclization and demtylation of n-(4-methoxyphenyl)-3-chloropropionamide; optimal base/solvent combinations | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-02-25 | — | — | US | claimed |
| US-20020137936-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)3-chloropropionamide | MENDELOVICI MARIOARA (IL) | 2002-09-26 | — | — | US | claimed |
| US-20020032333-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)-3-chloropropionamide | TEVA PHARMACEUTICAL USA, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2001070697-A1 | PROCESSES FOR PREPARING 6-HYDROXY-3,4-DIHYDROQUINOLINONE, CILOSTAZOL AND N-(4-METHOXYPHENYL)-3-CHLOROPROPIONAMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-09-27 | — | — | WO | claimed |
| CN-111285803-B | Preparation method of 6-hydroxy-3, 4-dihydro-2 (1H) -quinolone | 湖南复瑞生物医药技术有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-111285803-B | Preparation method of 6-hydroxy-3, 4-dihydro-2 (1H) -quinolone | 湖南复瑞生物医药技术有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-111285803-A | Preparation method of 6-hydroxy-3, 4-dihydro-2 (1H) -quinolone | 湖南复瑞生物医药技术有限责任公司 | 2020-06-16 | — | — | CN | disclosed |
| CN-111285803-A | Preparation method of 6-hydroxy-3, 4-dihydro-2 (1H) -quinolone | 湖南复瑞生物医药技术有限责任公司 | 2020-06-16 | — | — | CN | disclosed |
| US-8779146-B2 | Cilostazol cocrystals and compositions | NUFORMIX LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| WO-2001070697-A1 | PROCESSES FOR PREPARING 6-HYDROXY-3,4-DIHYDROQUINOLINONE, CILOSTAZOL AND N-(4-METHOXYPHENYL)-3-CHLOROPROPIONAMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070697-A1 | PROCESSES FOR PREPARING 6-HYDROXY-3,4-DIHYDROQUINOLINONE, CILOSTAZOL AND N-(4-METHOXYPHENYL)-3-CHLOROPROPIONAMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-09-27 | — | — | WO | disclosed |
| US-4058532-A | 1-Phenyl-3,4-dihydrocarbostyrils | STERLING DRUG INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4049715-A | 3-[2-(4-Anisidino)phenyl]-1-phenyl-1-propiophenones and propanols | STERLING DRUG INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-3994902-A | Certain 1,2-diphenyl-1,2,3,4-tetrahydroquinoline compounds | STERLING DRUG INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034228-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)-3-chloropropionamide | HRH2, HRH3, HRH4 | L3MBTL1 4357/4885ALDH1A1 203/4885HTT 799/4885 |
| US-20030176703-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)-3-chloropropionamide | HRH2, HRH3, HRH4 | L3MBTL1 4357/4885ALDH1A1 203/4885HTT 799/4885 |
| US-20020137936-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)3-chloropropionamide | HRH2, HRH3, PDE8B | L3MBTL1 4292/4885ALDH1A1 145/4885HTT 514/4885 |
| US-20020032333-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)-3-chloropropionamide | HRH2, HRH3, HRH4 | L3MBTL1 4357/4885ALDH1A1 203/4885HTT 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.